Stock Track | XTALPI Soars 15.91% on Opening Following $51 Million Drug Development Deal

Stock Track

Aug 06, 2025

XTALPI Holdings Ltd (02228.HK) shares surged 15.91% at the market open on Wednesday, following the announcement of a significant drug development agreement. The Hong Kong-listed artificial intelligence-driven drug discovery company has entered into a definitive agreement with Dovetree, marking a major step forward in its pharmaceutical research and development efforts.

According to the agreement, which was finalized in late June, XTALPI's unit will collaborate with Dovetree to discover and develop both small molecule and antibody drug candidates. This partnership leverages XTALPI's AI-powered drug discovery platform and could potentially accelerate the development of new therapeutic treatments, significantly boosting the company's position in the competitive pharmaceutical industry.

Investors responded positively to the news, particularly after XTALPI disclosed that it had received an initial payment of $51 million as of August 5. This substantial upfront payment not only validates the potential of the partnership but also provides XTALPI with additional capital to fund its ongoing research and development activities. The market's enthusiastic reaction suggests high expectations for the outcomes of this collaboration and its potential to drive future growth for XTALPI.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1137211992"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137211992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137211992?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137211992","market":"us","top_or_hot":-1,"title":"Stock Track | XTALPI Soars 15.91% on Opening Following $51 Million Drug Development Deal","media":"Stock Track","content":"<p>XTALPI Holdings Ltd (02228.HK) shares surged 15.91% at the market open on Wednesday, following the announcement of a significant drug development agreement. The Hong Kong-listed artificial intelligence-driven drug discovery company has entered into a definitive agreement with Dovetree, marking a major step forward in its pharmaceutical research and development efforts.</p>\n\n<p>According to the agreement, which was finalized in late June, XTALPI's unit will collaborate with Dovetree to discover and develop both small molecule and antibody drug candidates. This partnership leverages XTALPI's AI-powered drug discovery platform and could potentially accelerate the development of new therapeutic treatments, significantly boosting the company's position in the competitive pharmaceutical industry.</p>\n\n<p>Investors responded positively to the news, particularly after XTALPI disclosed that it had received an initial payment of $51 million as of August 5. This substantial upfront payment not only validates the potential of the partnership but also provides XTALPI with additional capital to fund its ongoing research and development activities. The market's enthusiastic reaction suggests high expectations for the outcomes of this collaboration and its potential to drive future growth for XTALPI.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | XTALPI Soars 15.91% on Opening Following $51 Million Drug Development Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | XTALPI Soars 15.91% on Opening Following $51 Million Drug Development Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XTALPI Holdings Ltd (02228.HK) shares surged 15.91% at the market open on Wednesday, following the announcement of a significant drug development agreement. The Hong Kong-listed artificial intelligence-driven drug discovery company has entered into a definitive agreement with Dovetree, marking a major step forward in its pharmaceutical research and development efforts.</p>\n\n<p>According to the agreement, which was finalized in late June, XTALPI's unit will collaborate with Dovetree to discover and develop both small molecule and antibody drug candidates. This partnership leverages XTALPI's AI-powered drug discovery platform and could potentially accelerate the development of new therapeutic treatments, significantly boosting the company's position in the competitive pharmaceutical industry.</p>\n\n<p>Investors responded positively to the news, particularly after XTALPI disclosed that it had received an initial payment of $51 million as of August 5. This substantial upfront payment not only validates the potential of the partnership but also provides XTALPI with additional capital to fund its ongoing research and development activities. The market's enthusiastic reaction suggests high expectations for the outcomes of this collaboration and its potential to drive future growth for XTALPI.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1137211992","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137211992","pubTimestamp":1754443890,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"XTALPI Holdings Ltd (02228.HK) shares surged 15.91% at the market open on Wednesday, following the announcement of a significant drug development agreement. The Hong Kong-listed artificial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"个股追踪|5100万美元药物开发交易后XTALPI开盘大涨15.91%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"XTALPI Holdings Ltd (02228.HK) shares surged 15.91% at the market open on Wednesday, following the announcement of a significant drug development agreement. The Hong Kong-listed artificial intelligence-driven drug discovery company has entered into a definitive agreement with Dovetree, marking a major step forward in its pharmaceutical research and development efforts.\nAccording to the agreement, which was finalized in late June, XTALPI's unit will collaborate with Dovetree to discover and develop both small molecule and antibody drug candidates. This partnership leverages XTALPI's AI-powered drug discovery platform and could potentially accelerate the development of new therapeutic treatments, significantly boosting the company's position in the competitive pharmaceutical industry.\nInvestors responded positively to the news, particularly after XTALPI disclosed that it had received an initial payment of $51 million as of August 5. This substantial upfront payment not only validates the potential of the partnership but also provides XTALPI with additional capital to fund its ongoing research and development activities. The market's enthusiastic reaction suggests high expectations for the outcomes of this collaboration and its potential to drive future growth for XTALPI.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}